Testing spesolimab for pyoderma gangrenosum skin ulcers
Treatments studied
Part of Skin clinical trials.
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of pyoderma gangrenosum with an active ulcer that's at least 2 inches across.
- Your ulcer must need treatment with strong medicine (not just creams or bandages).
- You cannot have other types of skin lesions or an ulcer that's bigger than about 4 inches across.
- You must be free of active infections (like tuberculosis, HIV, or hepatitis) or have completed treatment for them.
- Women who can get pregnant must use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether guselkumab (Tremfya) can help heal painful ulcers from Pyoderma Gangrenosum (PG). Participants must already be taking steroid medication and have a PG ulcer that is at least 4 cm².
This trial tests an injection called SHR-1139 for people with pyoderma gangrenosum (a rare skin condition that causes painful ulcers). If you have at least one ulcer that is 5 cm² or larger and your PARACELSUS score is at least 10, you may be able to join.
This study tests whether the drug bimekizumab can help heal ulcers caused by a rare skin condition called pyoderma gangrenosum (PG). If you have PG and are already taking prednisone, this trial may offer a new treatment option.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This study tests a cream called ruxolitinib for people with pyoderma gangrenosum, a condition that causes painful skin ulcers. The cream is applied directly to the ulcer, and the study aims to see if it helps heal the wounds.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.